Rexahn Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Rexahn Pharmaceuticals, Inc.
Public Company Edition: Follow-on offerings did not surge after ASCO, but Day One and Cogent raised $150m-plus. Also, IQVIA and Ionis sold $1.25bn and $500m in notes, while Krystal and Lexicon grossed $160m and $125m from post-approval offerings.
Amgen's Prolia appears to be the biggest drug on the list of products incurring price inflation penalties in Part B; many of the others have relatively low sales to Medicare.
Ten Chinese biotechs raised at least a combined $221m in venture capital and private equity deals after the turn of the year.
Terray/Calico tie-up will focus on small molecule discovery for diseases of aging, including cancer. Lilly, AstraZeneca sign discovery pacts with Nimbus and Illumina, respectively.
- Drug Delivery
- Site Specific
- Antisense, Oligonucleotides
- Large Molecule
- Nanotechnology, Chips, etc.
Drug Discovery Technologies
- Other Names / Subsidiaries
- Ocuphire Pharma, Inc.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.